TRPV1 and atherosclerosis: Our previous study demonstrated that chronic treatment of ApoE−/− mice with the TRPV1 agonist evodiamine alleviated hyperlipidemia, systemic inflammation, hepatic macrovesicular steatosis, and atherosclerosis [59].